ROBINS HARLAN S sold $10.8M of ADPT

ROBINS HARLAN S (Chief Scientific Officer) sold 492,400 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $21.89 ($21.72–$22.12, $10.78M total) across 2 trades on 2026-07-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROBINS HARLAN S
Published Jul 23, 2026, 11:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 23, 2026, 11:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, execution date, price range, and that it was conducted under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to change ADPT fundamentals on its own.

03

What to watch

The article does not state whether other insiders sold/bought around the same window, nor does it provide context on total compensation or prior sale cadence.

Relevance 6/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-23, covering sales executed 2026-07-21.

Background

The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

Form 4 shows CSO Robins Harlan S sold 492,400 ADPT shares in open-market trades totaling about $10.78M on 2026-07-21.

Expected impact

Near-term impact likely muted; any reaction would be more about overall insider-selling tone than fundamentals.

Evidence & confidence

The filing is a routine SEC Form 4 disclosure, specifies Rule 10b5-1 pre-arranged plan, and provides sale size and price range without any new company-specific operational or financial catalyst.

Market effects

No direct sector read-across; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, large insider sales can coincide with personal liquidity needs, but traders may still use it as a risk-management signal if selling accelerates.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the Form 4 insider transaction disclosure.

  • Robins Harlan S

    Chief Scientific Officer who sold shares.

  • Rule 10b5-1 plan

    Indicates the sale was pre-arranged, reducing discretionary-signal strength.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.